Navigation Links
Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
Date:1/26/2012

PARSIPPANY, N.J., Jan. 26, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc.- Florida has reached a settlement with Mallinckrodt Inc. on outstanding patent litigation related to Watson's generic versions of Mallinckrodt's Exalgo® (Hydromorphone Hydrochloride Extended-Release ) tablets.  Mallinckrodt filed its lawsuit on December 10, 2010 in the United States District Court for the District of New Jersey following Watson's filing of an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market its product in the 8 mg, 12 mg, and 16 mg dosage strengths.
Under terms of the settlement agreement, Mallinckrodt has granted Watson a royalty-free license to U.S. patents relating to Exalgo®.  Watson will have the right to launch its bioequivalent products on November 15, 2013.  Other details of the settlement were not disclosed.

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic version of Exalgo® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is an integrated global specialty pharmaceutical company. The Company is engaged in the development, manufacturing, marketing and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-h
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Watson Launches Generic Biaxin(R) XL
2. Watson Announces Positive Results From Its Pivotal Study of Oxybutynin Topical Gel for the Treatment of Overactive Bladder
3. Watson Announces Silodosin NDA Accepted for Filing by FDA for the Treatment of Benign Prostatic Hyperplasia
4. Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder
5. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
6. Watson and Barr Settle Lawsuit Over Oxytrol(R)
7. Watson to Host Conference Call and Webcast to Discuss Fourth Quarter 2009 Earnings and 2010 Outlook
8. Watson Completes Acquisition of Eden Biodesign
9. Watson to Present at Credit Suisse Healthcare Conference
10. Watson Announces New Program to Help Promote Good Bone Health in Advanced Prostate Cancer Patients on Long-Term Androgen Deprivation Therapy
11. Watson Files FDA Application for Generic Rozerem(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)...   BioNano Genomics announced today achievement of a ... human data at 30X depth, sufficient for a genome map, ... was established and demonstrated for the IrysChip TM V2, ... and will be rolled out to BioNano,s collaborators and ... this advancement at the American Society for Human Genetics ...
(Date:10/20/2014)... N.J. , Oct. 20, 2014   ... Pharmaceutical Co., Ltd. ( Japan ), ... (FDA) granted Fast Track designation for TAS-102 (nonproprietary ... anticancer drug under investigation for the treatment of ... Company has initiated a rolling NDA submission to ...
(Date:10/20/2014)... 20, 2014 Pharmaceutic Labs announces the opening ... Albany, NY for admixing, compounding, drug ... and/or exceeds the FDA standards for safety and quality, ... 211. The 10,000 square foot outsourcing ... quality assurance and quality control. The company will produce ...
Breaking Medicine Technology:BioNano Genomics Announces One Human : One Chip : One Day 2BioNano Genomics Announces One Human : One Chip : One Day 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... Companies, Inc. (NYSE: PRX ) announced today that ... Strativa Pharmaceuticals and Executive Vice President of Par Pharmaceutical Companies ...  Patrick G. LePore, Par Pharmaceutical Companies, Chairman, CEO and President, ... Patrick G. LePore states, "In ...
... Mylan Inc. (Nasdaq: MYL ) today confirmed that ... sued by Shionogi Pharma Inc. and CIMA LABS INC. in ... (ANDA) with the U.S. Food and Drug Administration (FDA) for ... and 30 mg. This product is the generic version of ...
Cached Medicine Technology:John A. MacPhee Resigns From Strativa Pharmaceuticals 2Mylan Confirms First-to-File Patent Challenge Relating to Orapred ODT® 2
(Date:10/19/2014)... Recently, BambooIndustry.com, one of the most popular suppliers ... bamboo deckings . Moreover, the company has launched ... now available at deeply discounted rates. , As ... overstate the significance of online business nowadays. Thus, BambooIndustry.com ... company’s workers are striving to deliver both value and ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 This ... for Partial Seizure, complete with comparative analysis at ... of action (MoA), route of administration (RoA) and ... news and press releases. It also reviews key ... Seizure and special features on late-stage and discontinued ...
(Date:10/19/2014)... Recently, Top10BestSEOHosting.com has unveiled its newest ... and HostMonster are the best VPS hosting suppliers ... is the method of partitioning a physical server ... the appearance and capabilities of running on someone’s ... pays close attention to VPS products and related ...
(Date:10/19/2014)... a professional company of women’s dresses and related accessories, ... dresses . All the company’s old and new client ... up to 66 percent off. , SweetDressy.com is ... Its dress specialists are striving to make more trendy ... world. All the company’s items are unique, graceful and ...
(Date:10/19/2014)... NY (PRWEB) October 20, 2014 Stephen T. ... has been nominated for the 10th consecutive year as one ... year Dr. Greenberg was also been nominated as the best ... was also nominated as best Day Spa and best Laser ... until December 14th and readers can vote for the contest ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Promotion For Beautiful Long Evening Dresses Launched By SweetDressy.com 2Health News:Dr. Stephen T. Greenberg – Nominated for the 10th Consecutive Year for One of Long Island’s Best Cosmetic Surgeons for 2015 by the Long Island Press 2
... Tice, Pharm.D., chief,clinical officer of PharmMD, will be ... at its upcoming annual meeting, scheduled,for March 14-17 ... career accomplishments, Dr. Tice helped make medication,therapy management ... the process of,preventing drug error, overuse and abuse ...
... Care Center at ... Hospital, and Nyack Hospital, HACKENSACK, N.J., March 17 ... anticipated debut in The Kennedy Funding,Invitational for 2008, July 9-13. ... hospital breast care centers. Co-Directors,James Miller, Mitch Klein, and Kevin ...
... people live with diabetes across the world and 4.4 ... diabetes control can lead to devastating complications, like blood ... which cause 85% of all amputations. , The Faculty ... Club of Rotary International has just received a grant ...
... . , Scientists at the University of ... Haemoglobin transports oxygen in the red blood corpuscles. When ... type appears optically to be transporting little oxygen. Measurements ... picture to patients suffering from an inherited cardiac defect. ...
... Well Tolerated in 26-Week Study, WILMINGTON, Del., ... of the maintenance combination asthma therapy,SYMBICORT(R) (budesonide/formoterol fumarate ... 11 years old. The study examined the,safety of ... included efficacy,measures. For children previously treated with inhaled ...
... Parents Reported -, PHILADELPHIA, March 17 Data ... silent epidemic among our nation,s children.,U.S. children are suffering ... to the Pediatric Allergies in America survey, which is,the ... children,under the age of 18 who suffer from allergic ...
Cached Medicine News:Health News:PharmMD's Brad Tice Named APhA Fellow 2Health News:PharmMD's Brad Tice Named APhA Fellow 3Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 2Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 3Health News:Superstar John McEnroe to Highlight The Kennedy Funding Invitational Tennis Tournament, July 9-13, 2008 4Health News:Egyptian foot care center recieves International Diabetes Federation grant 2Health News:Bonn scientists discover new hemoglobin type 2Health News:Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma 2Health News:Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma 3Health News:Study Analyzed Long-Term SYMBICORT(R) Use in Children With Persistent Asthma 4Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 2Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 3Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 4Health News:Landmark 'Pediatric Allergies in America' Survey Uncovered Negative Impact of Allergy Symptoms on Children 5
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... Hormone (FSH) is intimately involved in the ... of the gonadal tissues, which synthesize and ... The levels of circulating FSH is controlled ... feedback relationship. The FSH Quantitative Test ...
... Our Class II Direct to High Res SSP kits ... a single tray. Locus specific typing on a single ... , Straight from genomic DNA to high resolution ... Allele level typing with a single tray , Unique ...
... Res SSP kits provide high resolution typing of the ... on a single tray reduces QC and testing costs ... to high resolution results, no need for initial low ... tray , Unique reaction pattern for most common alleles ...
Medicine Products: